What is the 13F Pro Quality Score for NEPH?

13F Pro ranks NEPHROS INC (NEPH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View NEPH's current score at https://13fpro.ai/research/NEPH (free sign-up required for the full ranking).

Where does 13F Pro source NEPH data?

All NEPHROS INC fundamentals and ownership data come directly from SEC EDGAR. NEPHROS INC files with the SEC under CIK 1196298. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is NEPH in?

NEPHROS INC (NEPH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is NEPH research updated on 13F Pro?

NEPH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

NEPHROS INC(NEPH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1196298 NEPH stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $18.8M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

NEPH Stock Analysis & AI Quality Score

AI stock analysis and institutional research for NEPHROS INC (NEPH), a Healthcare sector company. NEPH is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $18.8m in revenue. Based on the latest XBRL financial filings (Q1 2026), NEPHROS INC reports quarterly revenue of $5.2M, net income of $140.0K, an operating margin of 1.9%. Top institutional holders of NEPH by reported 13-F value include WEXFORD CAPITAL, Topline Capital Management,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. NEPH trades on the Nasdaq exchange and files with the SEC under CIK 1196298. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NEPH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NEPHROS INC directly from SEC EDGAR.

Revenue

Q1 2026

$5.2M

Net Income

Q1 2026

$140.0K

Free Cash Flow

Q1 2026

$-1.7M

Operating Margin

Q1 2026

1.9%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+32.7% YoY

$18.8MFY 2025

FY21 $10.2MFY23 $14.2MFY24 $14.2MFY25 $18.8M

Net Income

+1513.5% YoY

$1.2MFY 2025

FY21 $-3.9MFY23 $-1.6MFY24 $74.0KFY25 $1.2M

Operating Income

+19000.0% YoY

$1.1MFY 2025

FY21 $-3.3MFY23 $-1.6MFY24 $6.0KFY25 $1.1M

EPS (Diluted)

+1000.0% YoY

$0.11FY 2025

FY21 —FY23 $-0.15FY24 $0.01FY25 $0.11

Total Assets

+21.7% YoY

$13.6MFY 2025

FY21 $17.6MFY23 $11.9MFY24 $11.2MFY25 $13.6M

Total Debt

—FY 2025

FY21 $343.0KFY23 —FY24 —FY25 —

Op. Cash Flow

+434.3% YoY

$1.6MFY 2025

FY21 $-1.4MFY23 $800.0KFY24 $-492.0KFY25 $1.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Revenue	$18.8M +32.7%	$14.2M -0.5%	$14.2M +39.4%	$10.2M +19.3%	$8.6M -17.2%	$10.3M
Net Income	$1.2M +1513.5%	$74.0K +104.7%	$-1.6M +59.3%	$-3.9M +14.6%	$-4.5M -42.4%	$-3.2M
Operating Income	$1.1M +19000.0%	$6.0K +100.4%	$-1.6M +51.0%	$-3.3M +23.9%	$-4.3M -35.5%	$-3.2M
EPS (Diluted)	$0.11 +1000.0%	$0.01 +106.7%	$-0.15	—	—	—
Total Assets	$13.6M +21.7%	$11.2M -5.5%	$11.9M -32.8%	$17.6M -4.6%	$18.5M +59.2%	$11.6M
Total Debt	—	—	—	$343.0K -42.2%	$593.0K -28.0%	$824.0K
Operating Cash Flow	$1.6M +434.3%	$-492.0K -161.5%	$800.0K +156.5%	$-1.4M +79.5%	$-6.9M -203.3%	$-2.3M

AI Insight: NEPH Financial Trends

NEPH revenue grew from $3M to $5M over eight quarters but operating cash flow turned negative to -$2M in Q1 2026.

• Revenue increased 67% from $3M in Q2 2024 to $5M in Q1 2026.

• Operating income improved from -$0M in Q2 2024 to breakeven levels since Q4 2024.

• Net income reached $1M in Q1 2025 before returning to breakeven.

⚠ Operating cash flow deteriorated to -$2M in Q1 2026 from $0M in prior quarter.

⚠ Revenue stalled at $5M for three consecutive quarters through Q1 2026.

AI Insight: NEPH Ratio Trends

NEPH's profitability deteriorated sharply in Q4 2025 and Q1 2026, with operating margin collapsing from 6.6% to 0.4% to 1.9%.

• Operating margin peaked at 11.6% in Q1 2025 before declining to 1.9% in Q1 2026.

• Net profit margin fell from 11.4% in Q1 2025 to 2.7% in Q1 2026.

• ROA dropped from 18.9% in Q1 2025 to 4.1% in Q1 2026.

⚠ Q4 2025 marked the lowest operating margin since Q2 2024's loss period.

⚠ TTM operating margin of 3.5% significantly trails recent quarterly peaks above 11%.

Get alerted when NEPH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for NEPHROS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of NEPH

WEXFORD CAPITAL LP
$10.7M3,600,552 sh
Topline Capital Management, LLC
$1.7M581,967 sh
VANGUARD CAPITAL MANAGEMENT LLC
$592.0K198,643 sh
Cornerstone Capital, Inc.
$383.5K128,700 sh
BARD ASSOCIATES INC
$361.2K121,202 sh
Mesirow Financial Investment Management, Inc.
$357.6K120,000 sh
MORGAN STANLEY
$330.5K110,915 sh
RENAISSANCE TECHNOLOGIES LLC
$296.2K99,400 sh
GEODE CAPITAL MANAGEMENT, LLC
$217.4K72,925 sh
HighTower Advisors, LLC
$177.9K59,710 sh

Fund	Value	Shares
WEXFORD CAPITAL LP	$10.7M	3,600,552
Topline Capital Management, LLC	$1.7M	581,967
VANGUARD CAPITAL MANAGEMENT LLC	$592.0K	198,643
Cornerstone Capital, Inc.	$383.5K	128,700
BARD ASSOCIATES INC	$361.2K	121,202
Mesirow Financial Investment Management, Inc.	$357.6K	120,000
MORGAN STANLEY	$330.5K	110,915
RENAISSANCE TECHNOLOGIES LLC	$296.2K	99,400
GEODE CAPITAL MANAGEMENT, LLC	$217.4K	72,925
HighTower Advisors, LLC	$177.9K	59,710

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put NEPH on your watchlist

Track score changes the day NEPHROS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is NEPH a good stock to buy?

13F Pro's AI-powered analysis of NEPHROS INC (NEPH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NEPH are available on the NEPH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own NEPH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NEPH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of NEPHROS INC's investment landscape.